PHARMACOSMOS A/S: Financial statements 2026
CVR: 15517085
Source: annual report 2026, Danish Business Authority
01/05/2025 – 30/04/2026
PHARMACOSMOS A/S (CVR 15517085) has filed annual accounts for 2026. In 2026, the company reported revenue of DKK 2,176,000,000 and a net result of DKK 714,000,000 compared with DKK 1,622,000,000 the year before. That is a decrease of 17% compared with the year before. The profit margin was 32.8%. Equity in the 2026 report amounted to DKK 2,775,000,000. The solvency ratio was 61.1%. The company had 286 employees in the financial year.
- Revenue
- DKK 2,176,000,000
- Gross Profit
- DKK 1,577,000,000
- Profit/Loss
- DKK 714,000,000
- Equity
- DKK 2,775,000,000
- Total Assets
- DKK 4,544,000,000
- Employees
- 286
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2026 | 2.2B | 1.6B | 714M | 2.8B | 286 |
| 2025 | 2.6B | 2.1B | 1.6B | 2.2B | 240 |
| 2024 | 1.6B | 1.2B | 789.7M | 1.6B | 208 |
| 2023 | 1.1B | 674.1M | 114.3M | 854.6M | 191 |
| 2022 | 876.8M | 545.5M | 170M | 807.5M | 468 |
Official annual report
Find more companies like PHARMACOSMOS A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2026
PHARMACOSMOS A/S has won the tender "Amgros 2027 1.204.a" issued by Amgros I/S worth 334,966,941 DKK.
About PHARMACOSMOS A/S
PHARMACOSMOS A/S is a Danish company of the type Aktieselskab based in Holbæk, founded in 1991. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named PHARMACOSMOS PHARMACEUTICALS A/S and SOLOCHEM A/S. The management consists of Tobias Sidelmann Christensen, Claes Christian Strøm and Henrik Parker. The board consists of Jacob Tolstrup (chair), Lars Christensen, Lars Green and Martin Holst Lange. The company is owned by PHARMACOSMOS HOLDING A/S. The company has 327 employees (2026). In 2026, the company reported revenue of DKK 2,176,000,000 and a net result of DKK 714,000,000 compared with DKK 1,622,000,000 the year before. Equity in the 2026 report amounted to DKK 2,775,000,000.